We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
  • FDA halts Bellicum trial over brain disease in participants, shares crash 48% pharmafile
    February 02, 2018
    Texas-based clinical-stage company Bellicum Pharmaceuticals has taken a massive stock hit after the FDA put a hold on its trials of its T-cell therapy BPX-501 due to three cases of encephalopathy in participants that are thought to be treatment-related.
  • NHL Veterans Pledge Their Brains to Research drugs.com
    February 24, 2017
PharmaSources Customer Service